The first indication that TAM signaling affects anti-tumor immunity came from genetic studies of Gas6-deficient mice, where absence of Gas6 in hematopoietic cells markedly impaired tumor proliferation and metastasis in diverse ectopic and orthotopic tumor models, including pancreatic, lymphoma, colon, breast, and melanoma tumors [27]. This evidence concerns the gene GAS6 and melanoma.